nach oben

Erschienen in:

2022 | Rauchen und Raucherentwöhnung | OriginalPaper | Buchkapitel

4. Behandlung von schädlichem und abhängigem Tabakkonsum

verfasst von : Stefan Andreas, Anil Batra, Dörthe Brüggmann, Dieter Geyer, Helmut Gohlke, Thomas Hering, Andreas Jähne, Julia Jückstock, Marianne Klein, Daniel Kotz, Christoph Kröger, Timo Krüger, Michael Kölch, Evelyn Lesta, Johannes Lindenmeyer, Peter Lindinger, Ute Mons, Stephan Mühlig, Tim Neumann, Kay Uwe Petersen, Thomas Polak, Ulrich W. Preuss, Martina Pötschke-Langer, Christa Rustler, Tobias Rüther, Sophie Luise Schiller, Christiane Schwarz, Cornelie Schweizer, Rainer Thomasius, Sabina Ulbricht, Clemens Veltrup

Erschienen in: S3-Leitlinie Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das vorliegende Kapitel bietet die Behandlungsempfehlungen der Tabakleitlinie mit ihren Hintergrundtexten. Es ist untergliedert in die Abschnitte Motivationsbehandlung und Kurzinterventionen, Harm Reduction, Psychotherapeutische Interventionen, Arzneimittel zur Entzugsbehandlung und Rückfallprophylaxe, Somatische Therapieverfahren, Gender- und Altersaspekte, Somatische Komorbidität, Psychische Komorbidität sowie Setting, Versorgungsorganisation und Aspekte der Finanzierung.

Ergänzende Position der DEGAM: Wenn eine leitliniengerecht durchgeführte medikamentöse Behandlung mit einer Nikotinersatztherapie nicht ausreichend wirksam war, soll der Einsatz von Bupropion zur Tabakentwöhnung angeboten werden.

Die Fachgesellschaft „Deutsche Gesellschaft für Suchtmedizin“ (DGS e.V.) ist der Auffassung, dass die elektronische Zigarette angesichts der Datenlage zur Unterstützung der Tabakabstinenz unter Beachtung von und nach Aufklärung über mögliche Risiken berücksichtigt werden sollte, wenn andere, evidenzbasierte Maßnahmen zur Erreichung einer Tabakabstinenz für Raucher nicht in Frage kommen. Die Fachgesellschaft bittet darum, bei der nächsten Überarbeitung der Leitlinie eine konsensbasierte Empfehlung auf Basis der vorhandenen Evidenz zu formulieren.

Die Fachgesellschaft „Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V.“ (DGP) hält die Risiken von E-Zigaretten insbesondere im dualen Konsum in der Darstellung der zuständigen Leitliniengruppe für unterschätzt. Die DGP kritisiert, dass mindestens eine Publikation (Polosa et al.) zitiert wird, die im Verdacht der Einflussnahme durch die E-Zigarettenindustrie steht. Eine Stellungnahme der DGP wurde in der Zeitschrift Pneumologie veröffentlicht (Pankow W, Andreas A, Rupp A, Pfeifer M. Tabakentwöhnung mit E-Zigarette? Pneumologie 2020: DOI: 10.1055/a-1323–6045).

Adelman WP. Tobacco use cessation for adolescents. Adolesc Med Clin. 2006;17(3):697–717.PubMed

Agboola S, McNeill A, Coleman T, Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction. 2010;105(8):1362–80.PubMedCrossRef

Akanbi MO, Carroll AJ, Achenbach C, O’Dwyer LC, Jordan N, Hitsman B, et al. The efficacy of smoking cessation interventions in low-and middle-income countries: a systematic review and meta-analysis. Addiction. 2019;114(4):620–35.PubMedPubMedCentralCrossRef

Alba LH, Murillo R, Becerra N, Páez N, Cañas A, Mosquera C, et al. Recommendations for smoking cessation in Colombia. Biomedica. 2013;33(2):186–204.PubMed

Albertson TE, Chenoweth J, Ford J, Owen K, Sutter ME. Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes? J Med Toxicol. 2014;10(4):369–81.PubMedPubMedCentralCrossRef

Aldi GA, Bertoli G, Ferraro F, Pezzuto A, Cosci F. Effectiveness of pharmacological or psychological interventions for smoking cessation in smokers with major depression or depressive symptoms: A systematic review of the literature. Subst Abus. 2018;39(3):289–306.PubMedCrossRef

Alghamdi F, Alhussien A, Alohali M, Alatawi A, Almusned T, Fecteau S, et al. Effect of transcranial direct current stimulation on the number of smoked cigarettes in tobacco smokers. PLoS One. 2019;14(2):e0212312.

Allen S. What determines the ability to stop smoking in old age? Age Ageing. 2008;37(5):490–1.PubMedCrossRef

Andreas S, Rittmeyer A, Hinterthaner M, Huber RM. Smoking cessation in lung cancer—achievable and effective. Dtsch Arztebl Int. 2013;110(43):719.PubMedPubMedCentral

Andreas S, Batra A, Behr J, Chenot JF, Gillissen A, Hering T, et al. Tabakentwöhnung bei COPD. Pneumologie. 2014;68(4):237–58.PubMedCrossRef

Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med. 2013;159(6):390–400.PubMedCrossRef

Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–20.PubMedCrossRef

Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233–9.PubMedCrossRef

Antoniewicz L, Brynedal A, Hedman L, Lundbäck M, Bosson JA. Acute effects of electronic cigarette inhalation on the vasculature and the conducting airways. Cardiovasc Toxicol. 2019;19(5):441–50.PubMedPubMedCentralCrossRef

Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev. 2016;(11):Art. No.: CD010274. https://doi.org/10.1002/14651858.CD010274.pub2.

Arzneimittelkommission der deutschen Ärzteschaft. Therapieempfehlungen Tabakabhängigkeit. Berlin;2010.

Asfar T, Ebbert JO, Klesges RC, Relyea GE. Do smoking reduction interventions promote cessation in smokers not ready to quit? Addict Behav. 2011;36(7):764–8.PubMedPubMedCentralCrossRef

Aspect Consortium. Tobacco or health in the European Union: Past, present and future. Luxembourg: Office for Official Publications of the European Communities;2004.

Aubin HJ, Luquiens A, Berlin I. Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. Br J Clin Pharmacol. 2014;77(2):324–36.PubMedPubMedCentralCrossRef

Audrain-McGovern J, Stevens S, Murray PJ, Kinsman S, Zuckoff A, Pletcher J, et al. The efficacy of motivational interviewing versus brief advice for adolescent smoking behavior change. Pediatrics. 2011;128(1):e101–e11.PubMedCrossRef

Bahl V, Lin S, Xu N, Davis B, Wang Y-H, Talbot P. Comparison of electronic cigarette refill fluid cytotoxicity using embryonic and adult models. Reprod Toxicol. 2012;34(4):529–37.PubMedCrossRef

Baraona LK, Lovelace D, Daniels JL, McDaniel L. Tobacco harms, nicotine pharmacology, and pharmacologic tobacco cessation interventions for women. J Midwifery Women’s Health. 2017;62(3):253–69.CrossRef

Barnes J, McRobbie H, Dong CY, Walker N, Hartmann-Boyce J. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev. 2019;(6):Art. No.: CD001008. https://doi.org/10.1002/14651858.CD001008.pub3.

Barth J, Jacob T, Daha I, Critchley JA. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev. 2015;(7):Art. No.: CD006886. https://doi.org/10.1002/14651858.CD006886.pub2.

Baser S, Shannon VR, Eapen GA, Jimenez CA, Onn A, Lin E, et al. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest. 2006;130(6):1784–90.PubMedCrossRef

Batra A. Therapie der Tabakabhängigkeit. Dtsch Ärzteb. 2011;108(38):555–64.

Batra A, Kröger C, Lindinger P, Pötschke-Langer M. Qualitätsmerkmale von Raucherbehandlungen–die Notwendigkeit für definierte Standards. Sucht. 2008;54(2):95–100.CrossRef

Batra A, Collins SE, Schröter M, Eck S, Torchalla I, Buchkremer G. A cluster-randomized effectiveness trial of smoking cessation modified for at-risk smoker subgroups. J Subst Abus Treat. 2010;38(2):128–40.CrossRef

Batra A, Jähne A, Rüther T. In: Voderholzer U, Hohagen F, Herausgeber. Therapie psychischer Erkrankungen. 15. Aufl. Heidelberg: Springer; 2020.

Bauld L, Brandling T, Templeton L. Facilitators and barriers to the delivery of school-based interventions to prevent the uptake of smoking among children: a systematic review of qualitative research: 2009. Res Gate. 2017.

Beard E, Shahab L, Cummings DM, Michie S, West R. New pharmacological agents to aid smoking cessation and tobacco harm reduction: what has been investigated, and what is in the pipeline? CNS Drugs. 2016;30(10):951–83.PubMedCrossRef

Behnam SG, Mousavi SA, Emamian MH. The effects of transcranial direct current stimulation compared to standard bupropion for the treatment of tobacco dependence: A randomized sham-controlled trial. Eur Psychiatry. 2019;60:41–8.CrossRef

Benowitz NL, Fraiman JB. Cardiovascular effects of electronic cigarettes. Nat Rev Cardiol. 2017;14(8):447.PubMedPubMedCentralCrossRef

Berlin I, Saïd S, Spreux-Varoquaux O, Launay JM, Olivares R, Millet V, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clini Pharmacol Ther. 1995;58(4):444–52.CrossRef

Berlin N, Cutter C, Battaglia C. Will preoperative smoking cessation programs generate long-term cessation? A systematic review and meta-analysis. Am J Manag Care. 2016;21:e623–e31.

Bernard P, Ninot G, Cyprien F, Courtet P, Guillaume S, Georgescu V, et al. Exercise and counseling for smoking cessation in smokers with depressive symptoms: a randomized controlled pilot trial. J Dual Diagn. 2015;11(3-4):205–16.PubMedCrossRef

Bhatt SP, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans Nicholas J, et al. Cigarette smoking and response to inhaled corticosteroids in COPD. Eur Respir J. 2018;51(1):1701393.PubMedCrossRef

Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003;98(10):1403–7.PubMedCrossRef

Blondal T, Gudmundsson LJ, Tomasson K, Jonsdottir D, Hilmarsdottir H, Kristjansson F, et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation-a randomized trial. Addiction. 1999a;94(7):1007–15.PubMedCrossRef

Bolliger CT, Zellweger J-P, Danielsson T, van Biljon X, Robidou A, Westin Å, et al. Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine Tob Res. 2002;4(4):433–9.PubMedCrossRef

van den Brand FA, Nagelhout GE, Reda AA, Winkens B, Evers SM, Kotz D, et al. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev. 2017;(9):Art. No.: CD004305. https://doi.org/10.1002/14651858.CD004305.pub5.

Bricker JB, Liu J, Comstock BA, Peterson AV, Kealey KA, Marek PM. Social cognitive mediators of adolescent smoking cessation: Results from a large randomized intervention trial. Psychol Addict Behav. 2010;24(3):436.PubMedPubMedCentralCrossRef

Brose LS, Simonavicius E, McNeill A. Maintaining abstinence from smoking after a period of enforced abstinence–systematic review, meta-analysis and analysis of behaviour change techniques with a focus on mental health. Psychol Med. 2018;48(4):669–78.PubMedCrossRef

Brown RA, Kahler CW, Niaura R, Abrams DB, Sales SD, Ramsey SE, et al. Cognitive–behavioral treatment for depression in smoking cessation. J Consult Clin Psychol. 2001;69(3):471.PubMedPubMedCentralCrossRef

Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW, Abrantes AM, et al. Bupropion and cognitive–behavioral treatment for depression in smoking cessation. Nicotine Tob Res. 2007;9(7):721–30.PubMedCrossRef

Brown RA, Abrantes AM, Strong DR, Niaura R, Kahler CW, Miller IW, et al. Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers. Nicotine Tob Res. 2014;16(2):197–207.PubMedCrossRef

Brown TJ, Todd A, O’Malley CL, Moore HJ, Husband AK, Bambra C, et al. Community pharmacy interventions for public health priorities: a systematic review of community pharmacy-delivered smoking, alcohol and weight management interventions. Public Health Res. 2016;4(2):1–162.CrossRef

Brown TJ, Hardeman W, Bauld L, Holland R, Maskrey V, Naughton F, et al. A systematic review of behaviour change techniques within interventions to prevent return to smoking postpartum. Addict Behav. 2019;92:236–43.PubMedPubMedCentralCrossRef

Bundesministerium für Gesundheit (BMG). Nationales Gesundheitsziel. Tabakkonsum reduzieren. Berlin: Bundesministerium für Gesundheit;2015.

Byars JA, Frost-Pineda K, Jacobs WS, Gold MS. Naltrexone augments the effects of nicotine replacement therapy in female smokers. J Addict Dis. 2005;24(2):49–60.PubMedCrossRef

Byerley BM, Haas DM. A systematic overview of the literature regarding group prenatal care for high-risk pregnant women. BMC Pregnancy Childbirth. 2017;17(1):329.PubMedPubMedCentralCrossRef

Cadham CJ, Jayasekera JC, Advani SM, Fallon SJ, Stephens JL, Braithwaite D, et al. Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis. Lung Cancer. 2019;135:205–16.PubMedCrossRef

Cahill K, Perera R. Quit and win contests for smoking cessation. Cochrane Database Syst Rev. 2008;(4):Art. No.: CD004986. https://doi.org/10.1002/14651858.CD004986.pub3.

Cahill K, Ussher MH. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev. 2011;(3):Art. No.: CD005353. https://doi.org/10.1002/14651858.CD005353.pub4.

Cahill K, Lancaster T, Green N. Stage-based interventions for smoking cessation. Cochrane Database Syst Rev. 2010;(11):Art. No.: CD004492. https://doi.org/10.1002/14651858.CD004492.pub4.

Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;(5):Art. No.: CD009329. https://doi.org/10.1002/14651858.CD009329.pub2.

Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016; 5. Art. No.: CD006103. https://doi.org/10.1002/14651858.CD006103.pub7.

Cañas A, Alba L-H, Becerra N, Murillo R, Páez N, Mosquera C, et al. Efficacy and safety of medication use for the cessation of tobacco addiction: a review of Clinical Practice Guidelines. Revista de Salud Públ. 2014;16(5):772–85.

Carson KV, Verbiest MEA, Crone MR, Brinn MP, Esterman AJ, Assendelft WJJ, et al. Training health professionals in smoking cessation. Cochrane Database Syst Rev. 2012;(5):Art. No.: CD000214. https://doi.org/10.1002/14651858.CD000214.pub2.

Carson-Chahhoud KV, Livingstone-Banks J, Sharrad KJ, Kopsaftis Z, Brinn MP, To-A-Nan R, et al. Community pharmacy personnel interventions for smoking cessation. Cochrane Database Syst Rev. 2019;(10):Art. No.: CD003698. https://doi.org/10.1002/14651858.CD003698.pub3.

Cataldo J. Clinical implications of smoking and aging: breaking through the barriers. J Gerontol Nurs. 2007;33(8):32–41.PubMedCrossRef

Centers for Disease Control and Prevention (CDC). Quitting smoking among adults--United States, 2001–2010. MMWR Morb Mortal Wkly Rep. 2011;60(44):1513–9.

Cerimele JM, Durango A. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies. J Clin Psychiatry. 2012;73(8):1039–47.CrossRef

Chae Y, Park H-J, Kang O-S, Lee H-J, Kim S-Y, Yin C-S, et al. Acupuncture attenuates autonomic responses to smoking-related visual cues. Compl Ther Med. 2011;19:S1–7.CrossRef

Chamberlain C, O’Mara-Eves A, Porter J, Coleman T, Perlen SM, Thomas J, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev. 2017;(2):Art. No.: CD001055. https://doi.org/10.1002/14651858.CD001055.pub5.:CD001055.

Chang P-H, Chiang C-H, Ho W-C, Wu P-Z, Tsai J-S, Guo F-R. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health. 2015;15(1):1–8.CrossRef

Chen D, Wu L-T. Smoking cessation interventions for adults aged 50 or older: a systematic review and meta-analysis. Drug Alcohol Depend. 2015;154:14–24.PubMedPubMedCentralCrossRef

Chu T-P, Chen M-L, Lin Y-C, Chen M-Y. The impact of innovative smoking reduction education at hospital entrances: a prospective pre-and post-test study design. Int J Environ Res Public Health. 2018;15(9):1922.PubMedCentralCrossRef

Cinciripini PM, Tsoh JY, Wetter DW, Lam C, De Moor C, Cinciripini L, et al. Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Exp Clin Psychopharmacol. 2005;13(4):282.PubMedCrossRef

Clair C, Mueller Y, Livingstone-Banks J, Burnand B, Camain JY, Cornuz J, et al. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev. 2019;(3):Art. No.: CD004705. https://doi.org/10.1002/14651858.CD004705.pub5.

Claire R, Chamberlain C, Davey MA, Cooper SE, Berlin I, Leonardi-Bee J, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2020;(3):Art. No.: CD010078. https://doi.org/10.1002/14651858.CD010078.pub3.

Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One. 2008;3(6):e2547.PubMedPubMedCentralCrossRef

Covey LS, Glassman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis. 1999;18(1):31–40.PubMedCrossRef

Covey LS, Glassman AH, Stetner F, Rivelli S, Stage K. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am J Psychiatr. 2002;159(10):1731–7.PubMedCrossRef

Cox LS, Patten CA, Niaura RS, Decker PA, Rigotti N, Sachs DP, et al. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med. 2004;19(8):828–34.PubMedPubMedCentralCrossRef

Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290(1):86–97.PubMedCrossRef

Czoli CD, Fong GT, Goniewicz ML, Hammond D. Biomarkers of exposure among „dual users“ of tobacco cigarettes and electronic cigarettes in Canada. Nicotine Tob Res. 2019;21(9):1259–66.PubMedCrossRef

Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology. 1999;21(2):195–202.PubMedCrossRef

Dalum P, Paludan-Müller G, Engholm G, Kok G. A cluster randomised controlled trial of an adolescent smoking cessation intervention: short and long-term effects. Scand J Public Health. 2012;40(2):167–76.PubMedCrossRef

David SP, Lancaster T, Stead LF, Evins AE, Cahill K. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev. 2006;(4):Art. No.: CD003086. https://doi.org/10.1002/14651858.CD003086.pub2.

Delgado-Charro MB, Guy RH. Effective use of transdermal drug delivery in children. Adv Drug Deliv Rev. 2014;73:63–82.PubMedCrossRef

Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications. CNS Drugs. 2001;15(6):469–94.PubMedCrossRef

Deutsche Krebsgesellschaft. Leitlinienprogramm Onkologie: Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms 2018 [Lang-version 1.0, AWMF-Registernummer: 020/07OL]. Available from: http://leitlinienprogramm-onkologie.de/Lungenkarzinom.98.0.html

Deutsches Krebsforschungszentrum (DKFZ). E-Zigaretten: Konsumverhalten in Deutschland 2014–2018. Aus der Wissenschaft – für die Politik. Heidelberg: Deutsches Krebsforschungszentrum;2018.

Deutsches Krebsforschungszentrum (DKFZ). E-Zigaretten und Tabakerhitzer – ein Überblick. Heidelberg: Deutsches Krebsforschungszentrum;2020.

Dhippayom T, Chaiyakunapruk N, Jongchansittho T. Safety of nortriptyline at equivalent therapeutic doses for smoking cessation. Drug Saf. 2011;34(3):199–210.PubMedCrossRef

Diehl A, Nakovics H, Mutschler J, Hermann D, Kiefer F. Rivastigmine reduces tobacco craving in alcohol-dependent smokers. Pharmacopsychiatry. 2009;42(03):89–94.PubMedCrossRef

Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328(7455):1519.PubMedPubMedCentralCrossRef

Donzé J, Ruffieux C, Cornuz J. Determinants of smoking and cessation in older women. Age Ageing. 2007;36(1):53–7.PubMedCrossRef

Doolan DM, Froelicher ES. Smoking cessation interventions and older adults. Prog Cardiovasc Nurs. 2008;23(3):119–27.PubMedCrossRef

Doolan DM, Stotts NA, Benowitz NL, Covinsky KE, Froelicher ES. The women’s initiative for nonsmoking (WINS) XI: age-related differences in smoking cessation responses among women with cardiovascular disease. Am J Geriatr Cardiol. 2008;17(1):37–47.PubMedCrossRef

Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry. 2001;58(6):565–72.PubMedCrossRef

Durlak JA, DuPre EP. Implementation matters: A review of research on the influence of implementation on program outcomes and the factors affecting implementation. Am J Community Psychol. 2008;41(3-4):327.PubMedCrossRef

Ebbert JO, Elrashidi MY, Stead LF. Interventions for smokeless tobacco use cessation. Cochrane Database Syst Rev. 2015;(10):Art. No.: CD004306. https://doi.org/10.1002/14651858.CD004306.pub5.

Ebbert J, Montori VM, Erwin PJ, Stead LF. Interventions for smokeless tobacco use cessation. Cochrane Database of Systematic Reviews 2011;(2):Art. No.: CD004306. https://doi.org/10.1002/14651858.CD004306.pub4.

van Eerd EA, van der Meer RM, van Schayck OC, Kotz D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;(8):Art. No.: CD010744. https://doi.org/10.1002/14651858.CD010744.pub2.

Eisenberg MJ, Blum LM, Filion KB, Rinfret S, Pilote L, Paradis G, et al. The efficacy of smoking cessation therapies in cardiac patients: a meta-analysis of randomized controlled trials. Can J Cardiol. 2010;26(2):73–9.PubMedPubMedCentralCrossRef

Elkins G, Marcus J, Bates J, Hasan Rajab M, Cook T. Intensive hypnotherapy for smoking cessation: a prospective study. Int J Clin Exp Hypn. 2006;54(3):303–15.PubMedCrossRef

Elrashidi MY, Ebbert JO. Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opin Emerg Drugs. 2014;19(2):243–60.PubMedCrossRef

European Network for Smoking and Tobacco Prevention (ENSP). Guidelines for treating tobacco dependence. Brüssel: European Network for Smoking and Tobacco Prevention;2018.

Evins AE, Culhane MA, Alpert JE, Pava J, Liese BS, Farabaugh A, et al. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmacol. 2008;28(6):660.PubMedPubMedCentralCrossRef

Evins AE, Pachas G, Mischoulon D, Urbanoski K, Carlini S, Sousa J, et al. A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. J Clin Psychopharmacol. 2011;31(5):597.PubMedPubMedCentralCrossRef

Faessel H, Ravva P, Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2009;31(1):177–89.PubMedCrossRef

Fagerström K, Rutqvist LE, Hughes JR. Snus as a smoking cessation aid: a randomized placebo-controlled trial. Nicotine Tob Res. 2012;14(3):306–12.PubMedCrossRef

Falcone M, Bernardo L, Wileyto EP, Allenby C, Burke AM, Hamilton R, et al. Lack of effect of transcranial direct current stimulation (tDCS) on short-term smoking cessation: Results of a randomized, sham-controlled clinical trial. Drug Alcohol Depend. 2019;194:244–51.PubMedCrossRef

Fanshawe TR, Halliwell W, Lindson N, Aveyard P, Livingstone-Banks J, Hartmann-Boyce J. Tobacco cessation interventions for young people. Cochrane Database Syst Rev. 2017;(11):Art. No.: CD003289. https://doi.org/10.1002/14651858.CD003289.pub6.

Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Datab Syst Rev. 2012;(1):Art. No.: CD006219. https://doi.org/10.1002/14651858.CD006219.pub3.

Faseru B, Richter KP, Scheuermann TS, Park EW. Enhancing partner support to improve smoking cessation. Cochrane Database Syst Rev. 2018;(8):Art. No.: CD002928. https://doi.org/10.1002/14651858.CD002928.pub4.

Ferguson J, Bauld L, Chesterman J, Judge K. The English smoking treatment services: one-year outcomes. Addiction. 2005;100:59–69.PubMedCrossRef

Ferguson J, Docherty G, Bauld L, Lewis S, Lorgelly P, Boyd KA, et al. Effect of offering different levels of support and free nicotine replacement therapy via an English national telephone quitline: randomised controlled trial. BMJ. 2012;344.

Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164.PubMedCrossRef

Fiore MC, Keller PA, Curry SJ. Health system changes to facilitate the delivery of tobacco-dependence treatment. Am J Prev Med. 2007;33(6):S349–S56.PubMedCrossRef

Fiore MC, Jaén C, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Departement of Health and Human Services Public Health Service; 2008.

Fitzgerald PJ. Elevated norepinephrine may be a unifying etiological factor in the abuse of a broad range of substances: alcohol, nicotine, marijuana, heroin, cocaine, and caffeine. Subs Abuse Res Treat. 2013;7:SART. S13019.CrossRef

Fixsen DL, Naoom SF, Blase KA, Friedman RM, Wallace F, Burns B, et al. Implementation research: a synthesis of the literature. 2005.

Flanders WD, Lally CA, Zhu B-P, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. Cancer Res. 2003;63(19):6556–62.PubMed

Franzen KF, Willig J, Cayo Talavera S, Meusel M, Sayk F, Reppel M, et al. E-cigarettes and cigarettes worsen peripheral and central hemodynamics as well as arterial stiffness: a randomized, double-blinded pilot study. Vasc Med. 2018;23(5):419–25.PubMedCrossRef

Frazer K, Callinan JE, McHugh J, van Baarsel S, Clarke A, Doherty K, et al. Legislative smoking bans for reducing harms from secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Datab Syst Rev. 2016;(2):Art. No.: CD005992. https://doi.org/10.1002/14651858.CD005992.pub3.

Fucito LM, Czabafy S, Hendricks PS, Kotsen C, Richardson D, Toll BA. Pairing smoking-cessation services with lung cancer screening: a clinical guideline from the association for the treatment of tobacco use and dependence and the society for research on nicotine and tobacco. Cancer. 2016;122(8):1150–9.PubMedCrossRef

Gallagher SM, Penn PE, Schindler E, Layne W. A comparison of smoking cessation treatments for persons with schizophrenia and other serious mental illnesses. J Psychoactive Drugs. 2007;39(4):487–97.PubMedCrossRef

Garces YI, Yang P, Parkinson J, Zhao X, Wampfler JA, Ebbert JO, et al. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest. 2004;126(6):1733–41.PubMedCrossRef

Gellert C, Schöttker B, Holleczek B, Stegmaier C, Müller H, Brenner H. Using rate advancement periods for communicating the benefits of quitting smoking to older smokers. Tob Control. 2013;22(4):227–30.PubMedCrossRef

George J, Hussain M, Vadiveloo T, Ireland S, Hopkinson P, Struthers AD, et al. Cardiovascular effects of switching from tobacco cigarettes to electronic cigarettes. J Am Coll Cardiol. 2019;74(25):3112–20.PubMedPubMedCentralCrossRef

George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O’Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;53(2):136–43.PubMedCrossRef

Gierisch JM, Bastian LA, Calhoun PS, McDuffie JR, Williams JW. Smoking cessation interventions for patients with depression: a systematic review and meta-analysis. J Gen Intern Med. 2012;27(3):351–60.PubMedCrossRef

Goecke M, Duhme K. Tabakprävention am Beispiel der „rauchfrei “-Kampagne. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018;61(11):1439–45.PubMedCrossRef

Gohlke H, Yusuf S. Quantitating loss of life by smoking a single cigarette. Clin Res Cardiol. 2007;96(7):522–3.PubMedCrossRef

Goldberg RW, Kreyenbuhl JA, Medoff DR, Dickerson FB, Wohlheiter K, Fang LJ, et al. Quality of diabetes care among adults with serious mental illness. Psychiatr Serv. 2007;58(4):536–43.PubMedCrossRef

Gómez-Coronado N, Walker AJ, Berk M, Dodd S. Current and emerging pharmacotherapies for cessation of tobacco smoking. Pharmacother J Hum Pharmacol Drug Ther. 2018;38(2):235–58.CrossRef

Goniewicz ML, Smith DM, Edwards KC, Blount BC, Caldwell KL, Feng J, et al. Comparison of nicotine and toxicant exposure in users of electronic cigarettes and combustible cigarettes. JAMA Netw Open. 2018;1(8):e185937-e.CrossRef

Gorelick DA, Zangen A, George MS. Transcranial magnetic stimulation (TMS) in the treatment of substance addiction. Ann N Y Acad Sci. 2014;1327(1):79.PubMedPubMedCentral

Gourlay SG, Stead LF, Benowitz N. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004;(3):Art. No.: CD000058. https://doi.org/10.1002/14651858.CD000058.pub2.

Graham AL, Carpenter KM, Cha S, Cole S, Jacobs MA, Raskob M, et al. Systematic review and meta-analysis of Internet interventions for smoking cessation among adults. Subst Abus Rehabil. 2016;7:55.CrossRef

Gray KM, Carpenter MJ, Lewis AL, Klintworth EM, Upadhyaya HP. Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial. Nicotine Tob Res. 2012;14(2):234–9.PubMedCrossRef

Green JP, Jay Lynn S, Montgomery GH. A meta-analysis of gender, smoking cessation, and hypnosis: a brief communication. Int J Clin Exp Hypn. 2006;54(2):224–33.PubMedCrossRef

Green JP, Lynn SJ, Montgomery GH. Gender-related differences in hypnosis-based treatments for smoking: a follow-up meta-analysis. Am J Clin Hypn. 2008;50(3):259–71.PubMedCrossRef

Griffiths SE, Parsons J, Naughton F, Fulton EA, Tombor I, Brown KE. Are digital interventions for smoking cessation in pregnancy effective? A systematic review and meta-analysis. Health Psychol Rev. 2018;12(4):333–56.PubMedCrossRef

Gupta H, Babu R. Transdermal delivery: product and patent update. Recent Pat Drug Deliv Formul. 2013;7(3):184–205.PubMedCrossRef

Haas AL, Muñoz RF, Humfleet GL, Reus VI, Hall SM. Influences of mood, depression history, and treatment modality on outcomes in smoking cessation. J Consult Clin Psychol. 2004;72(4):563.PubMedCrossRef

Hajek P, Stead LF. Aversive smoking for smoking cessation. Cochrane Database Syst Rev. 2001;(3):Art. No.: CD000546. https://doi.org/10.1002/14651858.CD000546.pub2.

Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380(7):629–37.PubMedCrossRef

Hall SM, Prochaska JJ. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol. 2009;5:409–31.PubMedPubMedCentralCrossRef

Hall SM, Muñoz RF, Reus VI. Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol. 1994;62(1):141.PubMedCrossRef

Hall SM, Muñoz RF, Reus VI, Sees KL, Duncan C, Humfleet GL, et al. Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. J Consult Clin Psychol. 1996;64(5):1003.PubMedCrossRef

Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry. 2002;59(10):930–6.PubMedCrossRef

Hall SM, Tsoh JY, Prochaska JJ, Eisendrath S, Rossi JS, Redding CA, et al. Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. Am J Public Health. 2006;96(10):1808–14.PubMedPubMedCentralCrossRef

Hall SM, Humfleet GL, Muñoz RF, Reus VI, Prochaska JJ, Robbins JA. Using extended cognitive behavioral treatment and medication to treat dependent smokers. Am J Public Health. 2011;101(12):2349–56.PubMedPubMedCentralCrossRef

Hanewinkel R, Isensee B. Risk factors for e-cigarette, conventional cigarette, and dual use in German adolescents: a cohort study. Prev Med. 2015;74:59–62.PubMedCrossRef

Hanna N, Mulshine J, Wollins DS, Tyne C, Dresler C. Tobacco cessation and control a decade later: American society of clinical oncology policy statement update. J Clin Oncol. 2013;31(25):3147–57.PubMedCrossRef

Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev. 2012;(8):Art. No.: CD007072. https://doi.org/10.1002/14651858.CD007072.pub2.

Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction. 2014;109(9):1414–25.PubMedCrossRef

Hartmann-Boyce J, McRobbie H, Bullen C, Begh R, Stead LF, Hajek P. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2016;(9):Art. No.: CD010216. https://doi.org/10.1002/14651858.CD010216.pub3.

Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;(5):Art. No.: CD000146. https://doi.org/10.1002/14651858.CD000146.pub5.

Hartmann-Boyce J, Hong B, Livingstone-Banks J, Wheat H, Fanshawe TR. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2019;(6):Art. No.: CD009670. https://doi.org/10.1002/14651858.CD009670.pub4.

Haskins BL, Lesperance D, Gibbons P, Boudreaux ED. A systematic review of smartphone applications for smoking cessation. Transl Behav Med. 2017;7(2):292–9.PubMedPubMedCentralCrossRef

Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62(12):1049–53.PubMedCrossRef

Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clini Pharmacol Ther. 2011;89(3):392–9.CrossRef

Hauer L, Scarano GI, Brigo F, Golaszewski S, Lochner P, Trinka E, et al. Effects of repetitive transcranial magnetic stimulation on nicotine consumption and craving: a systematic review. Psychiatry Res. 2019;281:112562.PubMedCrossRef

Haustein K, Krause J, Haustein H, Rasmussen T, Cort N. Changes in hemorheological and biochemical parameters following short-term and long-term smoking cessation induced by nicotine replacement therapy (NRT). Int J Clin Pharmacol Ther. 2004;42(2):83–92.PubMedCrossRef

Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry. 1999;174:173–8.PubMedCrossRef

Hecht SS, Carmella SG, Murphy SE, Riley WT, Le C, Luo X, et al. Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiol Prev Biomarkers. 2007;16(8):1567–72.CrossRef

Heckman CJ, Egleston BL, Hofmann MT. Efficacy of motivational interviewing for smoking cessation: a systematic review and meta-analysis. Tob Control. 2010;19(5):410–6.PubMedCrossRef

Herold R, Schiekirka S, Brown J, Bobak A, McEwen A, Raupach T. Structured smoking cessation training for medical students: a prospective study. Nicotine Tob Res. 2016;18(12):2209–15.PubMedPubMedCentralCrossRef

Herr C, Beisswenger C, Hess C, Kandler K, Suttorp N, Welte T, et al. Suppression of pulmonary innate host defence in smokers. Thorax. 2009;64(2):144.PubMedCrossRef

Herth F, Reinmuth N, Wormanns D, Antoch G, Biederer J, Vogel-Claussen J, et al. Positionspapier der Deutschen Röntgengesellschaft und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zu einem qualitätsgesicherten Früherkennungsprogramm des Lungenkarzinoms mittels Niedrigdosis-CT. Pneumologie. 2019;73(10):573–7.PubMedCrossRef

Hippisley-Cox J, Parker C, Coupland C, Vinogradova Y. Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart. 2007;93(10):1256–62.PubMedPubMedCentralCrossRef

Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009;85(6):635–43.PubMedCrossRef

Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ. 2016;352:i11202.

Hollands GJ, Naughton F, Farley A, Lindson N, Aveyard P. Interventions to increase adherence to medications for tobacco dependence. Cochrane Database Syst Rev. 2019;(8):Art. No.: CD009164. https://doi.org/10.1002/14651858.CD009164.pub3.

Hollis JF, Polen MR, Whitlock EP, Lichtenstein E, Mullooly JP, Velicer WF, et al. Teen reach: outcomes from a randomized, controlled trial of a tobacco reduction program for teens seen in primary medical care. Pediatrics. 2005;115(4):981–9.PubMedCrossRef

Horst WD, Klein MW, Williams D, Werder SF. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. Neuropsychiatr Dis Treat. 2005;1(4):349.

Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2020;(4):Art. No.: CD000031. https://doi.org/10.1002/14651858.CD000031.pub5.

Hughes JR, Carpenter MJ. The feasibility of smoking reduction: an update. Addiction. 2005;100(8):1074–89.PubMedPubMedCentralCrossRef

Hughes JR, Carpenter MJ. Does smoking reduction increase future cessation and decrease disease risk? A qualitative review. Nicotine Tob Res. 2006;8(6):739–49.PubMedCrossRef

Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev. 2000;(4):Art. No.: CD002849. https://doi.org/10.1002/14651858.CD002849.

Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007;(1):Art. No.: CD000031. https://doi.org/10.1002/14651858.CD000031.pub3.

Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;(1):Art. No.: CD000031. https://doi.org/10.1002/14651858.CD000031.pub4.

Hummel K, Nagelhout GE, Fong GT, Vardavas CI, Papadakis S, Herbeć A, et al. Quitting activity and use of cessation assistance reported by smokers in eight European countries: findings from the EUREST-PLUS ITC Europe Surveys. Tob Induc Dis. 2018;16.

Huttunen-Lenz M, Song F, Poland F. Are psychoeducational smoking cessation interventions for coronary heart disease patients effective? Meta-analysis of interventions. Br J Health Psychol. 2010;15(4):749–77.

Japuntich SJ, Smith SS, Jorenby DE, Piper ME, Fiore MC, Baker TB. Depression predicts smoking early but not late in a quit attempt. Nicotine Tob Res. 2007;9(6):677–86.PubMedCrossRef

Javitz HS, Swan GE, Lerman C. The dynamics of the urge-to-smoke following smoking cessation via pharmacotherapy. Addiction. 2011;106(10):1835–45.PubMedCrossRef

Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-Century Hazards of Smoking and Benefits of Cessation in the United States. N Engl J Med. 2013;368(4):341–50.PubMedCrossRef

Jiménez-Ruiz CA, Andreas S, Lewis KE, Tonnesen P, van Schayck CP, Hajek P, et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. Eur Respir J. 2015;46(1):61–79.PubMedCrossRef

Jit M, Barton P, Chen Y, Uthman O, Aveyard P, Meads C. School-based interventions to prevent the uptake of smoking among children and young people: cost-effectiveness model. Birmingham: West Midlands Health Technology Assessment Collaboration;2009.

Jones HA, Heffner JL, Mercer L, Wyszynski CM, Vilardaga R, Bricker JB. Web-based acceptance and commitment therapy smoking cessation treatment for smokers with depressive symptoms. J Dual Diagn. 2015;11(1):56–62.PubMedPubMedCentralCrossRef

Joossens L, Feliu A, Fernandez E. The tobacco control scale 2019 in Europe Brussels: association of European Cancer Leagues, Catalan Institute of Oncology; 2020.

Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs. 2002;62(2):25–35.PubMedCrossRef

Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340(9):685–91.PubMedCrossRef

Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335(24):1792–8.PubMedCrossRef

Judge K, Bauld L, Chesterman J, Ferguson J. The English smoking treatment services: short-term outcomes. Addiction. 2005;100:46–58.PubMedCrossRef

Juliano LM, Houtsmuller EJ, Stitzer ML. A preliminary investigation of rapid smoking as a lapse-responsive treatment for tobacco dependence. Exp Clin Psychopharmacol. 2006;14(4):429.PubMedCrossRef

Kastaun S, Kotz D. Ärztliche Kurzberatung zur Tabakentwöhnung – Ergebnisse der DEBRA Studie. Sucht. 2019;65(1):34–41.CrossRef

Kastaun S, Leve V, Hildebrandt J, Funke C, Klosterhalfen S, Lubisch D, et al. Training general practitioners in the ABC versus 5As method of delivering stop-smoking advice: a pragmatic, two-arm cluster randomised controlled trial. ERJ Open Res. 2020.

Keith RJ, Fetterman JL, Orimoloye OA, Dardari Z, Lorkiewicz PK, Hamburg NM, et al. Characterization of volatile organic compound metabolites in cigarette smokers, electronic nicotine device users, dual users, and nonusers of tobacco. Nicotine Tob Res. 2020;22(2):264–72.PubMedCrossRef

Kerr S, Watson H, Tolson D, Lough M, Brown M. Smoking after the age of 65 years: a qualitative exploration of older current and former smokers’ views on smoking, stopping smoking, and smoking cessation resources and services. Health Soc Care Commun. 2006;14(6):572–82.CrossRef

Kerr S, Watson H, Tolson D, Lough M, Brown M. An exploration of the knowledge, attitudes and practice of members of the primary care team in relation to smoking and smoking cessation in later life. Prim Health Care Res Dev. 2007;8(1):68–79.CrossRef

Killen JD, Fortmann SP, Schatzberg AF, Hayward C, Sussman L, Rothman M, et al. Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol. 2000;68(5):883.PubMedCrossRef

Killen JD, Robinson TN, Ammerman S, Hayward C, Rogers J, Stone C, et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol. 2004;72(4):729.PubMedCrossRef

Killen JD, Fortmann SP, Schatzberg AF, Arredondo C, Murphy G, Hayward C, et al. Extended cognitive behavior therapy for cigarette smoking cessation. Addiction. 2008;103(8):1381–90.PubMedPubMedCentralCrossRef

Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Fong D, Lowenthal K, et al. Failure to improve cigarette smoking abstinence with transdermal selegiline+ cognitive behavior therapy. Addiction. 2010;105(9):1660–8.PubMedPubMedCentralCrossRef

Kim Y, Myung S-K, Jeon Y-J, Lee E-H, Park C-H, Seo HG, et al. Effectiveness of pharmacologic therapy for smoking cessation in adolescent smokers: Meta-analysis of randomized controlled trials. Am J Health Syst Pharm. 2011;68(3):219–26.PubMedCrossRef

King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res. 2006;8(5):671–82.PubMedCrossRef

King AC, Smith LJ, McNamara PJ, Matthews AK, Fridberg DJ. Passive exposure to electronic cigarette (e-cigarette) use increases desire for combustible and e-cigarettes in young adult smokers. Tob Control. 2015;24(5):501–4.PubMedCrossRef

Kinnunen T, Doherty K, Militello FS, Garvey AJ. Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement. J Consult Clin Psychol. 1996;64(4):791.PubMedCrossRef

Kinnunen T, Korhonen T, Garvey AJ. Role of nicotine gum and pretreatment depressive symptoms in smoking cessation: twelve-month results of a randomized placebo controlled trial. Int J Psychiatr Med. 2008;38(3):373–89.CrossRef

Kishi T, Iwata N. Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2015;265(3):259–68.PubMedCrossRef

Klemp I, Steffenssen M, Bakholdt V, Thygesen T, Sørensen JA. Counseling is effective for smoking cessation in head and neck cancer patients-a systematic review and meta-analysis. J Oral Maxillofac Surg. 2016;74(8):1687–94.PubMedCrossRef

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.PubMedCrossRef

Kotz D, Böckmann M, Kastaun S. Nutzung von Tabak und E-Zigaretten sowie Methoden zur Tabakentwöhnung in Deutschland. Eine repräsentative Befragung in 6 Wellen über 12 Monate (die DEBRA-Studie). Dtsch Arztebl Int. 2018;115:235–42.PubMedPubMedCentral

Kotz D, Batra A, Kastaun S. Rauchstoppversuche und genutzte Entwöhnungsmethoden. Dtsch Arztebl Int. 2020;117(1-2):7–13.PubMedPubMedCentral

Kralikova E, Kozak JT, Rasmussen T, Gustavsson G, Le Houezec J. Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler. BMC Public Health. 2009;9(1):433.PubMedPubMedCentralCrossRef

Krishnan-Sarin S, Duhig AM, McKee SA, McMahon TJ, Liss T, McFetridge A, et al. Contingency management for smoking cessation in adolescent smokers. Exp Clin Psychopharmacol. 2006;14(3):306.PubMedCrossRef

Kumar R, Prasad R. Smoking cessation: an update. Indian J Chest Dis Allied Sci. 2014;56:161–9.PubMed

Kumar S, Kodela S, Detweiler JG, Kim KY, Detweiler MB. Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature. Gen Hosp Psychiatry. 2011;33(6):612–7.PubMedCrossRef

Lancaster T, Stead LF. Silver acetate for smoking cessation. Cochrane Database Syst Rev. 2012;(9):Art. No.: CD000191. https://doi.org/10.1002/14651858.CD000191.pub2.

Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2017;(3):Art. No.: CD001292. https://doi.org/10.1002/14651858.CD001292.pub3.

Laniado-Laborín R. Smoking cessation intervention: an evidence-based approach. Postgrad Med. 2010;122(2):74–82.PubMedCrossRef

Le Houezec J, Aubin H-J. Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence. Expert Opin Pharmacother. 2013;14(14):1959–67.PubMedCrossRef

Leaviss J, Sullivan W, Ren S, Everson-Hock E, Stevenson M, Stevens JW, et al. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. Health Technol Assess. 2014;18(33).

Lee EB, An W, Levin ME, Twohig MP. An initial meta-analysis of acceptance and commitment therapy for treating substance use disorders. Drug Alcohol Depend. 2015;155:1–7.PubMedCrossRef

Lee S-H, Ahn S-H, Cheong Y-S. Effect of electronic cigarettes on smoking reduction and cessation in Korean male smokers: a randomized controlled study. J Am Board Fam Med. 2019;32(4):567–74.PubMedCrossRef

Lightwood JM, Glantz SA. Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation. 2009;120(14):1373–9.

Lindinger P, Strunk M, Nübling M, Lang P. Arbeitsweise und Wirksamkeit einer Telefonberatung für Tabakentwöhnung. Sucht. 2012;58(1):33–43.CrossRef

Lindson N, Thompson TP, Ferrey A, Lambert JD, Aveyard P. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2019a;(7):Art. No.: CD006936. https://doi.org/10.1002/14651858.CD006936.pub4.

Lindson N, Klemperer E, Hong B, Ordóñez-Mena JM, Aveyard P. Smoking reduction interventions for smoking cessation. Cochrane Database Syst Rev. 2019b;(9):Art. No.: CD013183. https://doi.org/10.1002/14651858.CD013183.pub2.

Lindson-Hawley N, Thompson TP, Begh R. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2015;(3):Art. No.: CD006936. https://doi.org/10.1002/14651858.CD006936.pub3.

Lindson-Hawley N, Hartmann-Boyce J, Fanshawe TR, Begh R, Farley A, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev. 2016;(10):Art. No.: CD005231. https://doi.org/10.1002/14651858.CD005231.pub3.

Livingstone-Banks J, Ordóñez-Mena JM, Hartmann-Boyce J. Print-based self-help interventions for smoking cessation. Cochrane Database Syst Rev. 2019a;(1) Art. No.: CD001118. https://doi.org/10.1002/14651858.CD001118.pub4.

Livingstone-Banks J, Norris E, Hartmann-Boyce J, West R, Jarvis M, Chubb E, et al. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev. 2019b;(10):Art. No.: CD003999. https://doi.org/10.1002/14651858.CD003999.pub6.

Lucchiari C, Masiero M, Mazzocco K, Veronesi G, Maisonneuve P, Jemos C, et al. Benefits of e-cigarettes in smoking reduction and in pulmonary health among chronic smokers undergoing a lung cancer screening program at 6 months. Addict Behav. 2020;103:106222.PubMedCrossRef

Maci E, Comito F, Frezza AM, Tonini G, Pezzuto A. Lung nodule and functional changes in smokers after smoking cessation short-term treatment. Cancer Investig. 2014;32(8):388–93.CrossRef

MacPherson L, Tull MT, Matusiewicz AK, Rodman S, Strong DR, Kahler CW, et al. Randomized controlled trial of behavioral activation smoking cessation treatment for smokers with elevated depressive symptoms. J Consult Clin Psychol. 2010;78(1):55.PubMedPubMedCentralCrossRef

Maglione MA, Maher AR, Ewing B, Colaiaco B, Newberry S, Kandrack R, et al. Efficacy of mindfulness meditation for smoking cessation: a systematic review and meta-analysis. Addict Behav. 2017;69:27–34.PubMedCrossRef

Mallock N, Pieper E, Hutzler C, Henkler-Stephani F, Luch A. Heated tobacco products: a review of current knowledge and initial assessments. Front Public Health. 2019;7:287.PubMedPubMedCentralCrossRef

Mannelli P, Wu L-T, Peindl KS, Gorelick DA. Smoking and opioid detoxification: behavioral changes and response to treatment. Nicotine Tob Res. 2013;15(10):1705–13.PubMedPubMedCentralCrossRef

Marques-Vidal P, Melich-Cerveira J, Paccaud F, Waeber G, Vollenweider P, Cornuz J. High expectation in non-evidence-based smoking cessation interventions among smokers – the CoLaus study. Prev Med. 2011;52(3-4):258–61.PubMed

Matkin W, Ordóñez-Mena JM, Hartmann-Boyce J. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2019;(5):Art. No.: CD002850. https://doi.org/10.1002/14651858.CD002850.pub4.

Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35(7):2031–40.PubMedCrossRef

McKee SA, Weinberger AH, Harrison EL, Coppola S, George TP. Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study. Schizophr Res. 2009;115(2-3):317–24.PubMedPubMedCentralCrossRef

McKee SA, Smith PH, Kaufman M, Mazure CM, Weinberger AH. Sex differences in varenicline efficacy for smoking cessation: a meta-analysis. Nicotine Tob Res. 2016;18(5):1002–11.PubMedCrossRef

McRobbie H, Bullen C, Glover M, Whittaker R, Wallace-Bell M, Fraser T. New Zealand smoking cessation guidelines. N Z Med J. 2008;121(1276):57–70.PubMed

McRobbie H, Thornley S, Bullen C, Lin RB, Senior H, Laugesen M, et al. A randomized trial of the effects of two novel nicotine replacement therapies on tobacco withdrawal symptoms and user satisfaction. Addiction. 2010;105(7):1290–8.PubMedCrossRef

McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev. 2014;12:Art. No.: CD010216. https://doi.org/10.1002/14651858.CD010216.pub2.CrossRef

McVay MA, Copeland AL. Smoking cessation in peri- and postmenopausal women: a review. Exp Clin Psychopharmacol. 2011;19(3):192–202.PubMedCrossRef

van der Meer RM, Willemsen MC, Smit F, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev. 2013;(8):Art. No.: CD006102. https://doi.org/10.1002/14651858.CD006102.pub2.

Meyers DG, Neuberger JS, He J. Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;54(14):1249–55.PubMedCrossRef

Michie S, Van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):42.PubMedPubMedCentralCrossRef

Miller W, Rollnick S. Motivational interviewing: Preparing people for change. New York: Guilford Press;2002.

Mills E, Eyawo O, Lockhart I, Kelly S, Wu P, Ebbert JO. Smoking cessation reduces postoperative complications: a systematic review and meta-analysis. Am J Med. 2011;124(2):144–54.PubMedCrossRef

Mitchell AJ, Vancampfort D, De Hert M, Stubbs B. Do people with mental illness receive adequate smoking cessation advice? A systematic review and meta-analysis. Gen Hosp Psychiatry. 2015;37(1):14–23.PubMedCrossRef

Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007;131(2):446–52.PubMedCrossRef

Mons U, Kahnert S. Neuberechnung der tabakattributablen Mortalität – Nationale und regionale Daten für Deutschland. Gesundheitswesen. 2019;81(01):24–33.PubMedCrossRef

Monuteaux MC, Spencer TJ, Faraone SV, Wilson AM, Biederman J. A randomized, placebo-controlled clinical trial of bupropion for the prevention of smoking in children and adolescents with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2007;68(7):1094–101.PubMedCrossRef

Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth WB, Heishman SJ, et al. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction. Pediatrics. 2005;115(4):e407–e14.PubMedCrossRef

Morrison MF, Ceesay P, Gantz I, Kaufman KD, Lines CR. Randomized, controlled, double-blind trial of taranabant for smoking cessation. Psychopharmacology. 2010;209(3):245–53.PubMedCrossRef

Mottillo S, Filion KB, Belisle P, Joseph L, Gervais A, O’Loughlin J, et al. Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30(6):718–30.PubMedCrossRef

Muilenburg JL, Laschober TC, Eby LT. Substance use disorder counselors’ reports of tobacco cessation services availability, implementation, and tobacco-related knowledge. J Adolesc Health. 2015;57(3):327–33.PubMedPubMedCentralCrossRef

Mullen KA, Walker KL, Hobler LA, Wells GA, Moroz IA, Pipe AL, et al. Performance obligations to improve delivery of hospital-initiated smoking cessation interventions: a before-and-after evaluation. Nicotine Tob Res. 20191–9.

Muramoto ML, Leischow SJ, Sherrill D, Matthews E, Strayer LJ. Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med. 2007;161(11):1068–74.PubMedCrossRef

National Academies of Sciences, Engineering, and Medicine (NASEM). Public health consequences of e-cigarettes. National Academies Press;2018.

National Institute for Health and Care Excellence (NICE). Stop Smoking Interventions and Services. London: NICE;2018.

Nelson PR, Chen P, Battista DR, Pillitteri JL, Shiffman S. Randomized trial to compare smoking cessation rates of snus, with and without smokeless tobacco health-related information, and a nicotine lozenge. Nicotine Tob Res. 2019;21(1):88–94.PubMedCrossRef

Niaura R. Nonpharmacologic therapy for smoking cessation: characteristics and efficacy of current approaches. Am J Med. 2008;121(4, Supplement):S11–S9.PubMedCrossRef

Niaura R, Abrams DB. Smoking cessation: Progress, priorities, and prospectus. J Consult Clin Psychol. 2002;70(3):494.PubMedCrossRef

Notley C, Gentry S, Livingstone-Banks J, Bauld L, Perera R, Hartmann-Boyce J. Incentives for smoking cessation. Cochrane Database Syst Rev. 2019;(7):Art. No.: CD004307. https://doi.org/10.1002/14651858.CD004307.pub6.

O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):485–510.PubMed

Oikonomou MT, Arvanitis M, Sokolove RL. Mindfulness training for smoking cessation: a meta-analysis of randomized-controlled trials. J Health Psychol. 2017;22(14):1841–50.PubMedCrossRef

Olivier D, Lubman DI, Fraser R. Tobacco smoking within psychiatric inpatient settings: biopsychosocial perspective. Austr N Z J Psychiatry. 2007;41(7):572–80.CrossRef

Pan A, Wang Y, Talaei M, Hu FB. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation. 2015;132(19):1795–804.PubMedPubMedCentralCrossRef

Pandeya N, Williams GM, Sadhegi S, Green AC, Webb PM, Whiteman DC. Associations of duration, intensity, and quantity of smoking with adenocarcinoma and squamous cell carcinoma of the esophagus. Am J Epidemiol. 2008;168(1):105–14.PubMedCrossRef

Park E, Drake E. Systematic review: internet-based program for youth smoking prevention and cessation. J Nurs Scholarsh. 2015;47(1):43–50.PubMedCrossRef

Parsons A, Ingram J, Inglis J, Aveyard P, Johnstone E, Brown K, et al. A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John’s wort for smoking cessation and chromium to prevent weight gain on smoking cessation. Drug Alcohol Depend. 2009;102(1-3):116–22.PubMedCrossRef

Patten CA, Bronars CA, Vickers Douglas KS, Ussher MH, Levine JA, Tye SJ, et al. Supervised, vigorous intensity exercise intervention for depressed female smokers: a pilot study. Nicotine Tob Res. 2016;19(1):77–86.PubMedPubMedCentralCrossRef

Pbert L, Druker S, DiFranza JR, Gorak D, Reed G, Magner R, et al. Effectiveness of a school nurse–delivered smoking-cessation intervention for adolescents. Pediatrics. 2011;128(5):926–36.PubMedPubMedCentralCrossRef

Peckham E, Brabyn S, Cook L, Tew G, Gilbody S. Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis. BMC psychiatry. 2017;17(1):252.PubMedPubMedCentralCrossRef

Peirson L, Ali MU, Kenny M, Raina P, Sherifali D. Interventions for prevention and treatment of tobacco smoking in school-aged children and adolescents: a systematic review and meta-analysis. Prev Med. 2016;85:20–31.PubMedCrossRef

Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res. 2008;10(7):1245–50.PubMedCrossRef

Pieper E, Mallock N, Henkler-Stephani F, Luch A. Tabakerhitzer als neues Produkt der Tabakindustrie: Gesundheitliche Risiken. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018;61(11):1422–8.PubMedCrossRef

Piñeiro B, Simmons VN, Palmer AM, Correa JB, Brandon TH. Smoking cessation interventions within the context of low-dose computed tomography lung cancer screening: a systematic review. Lung Cancer. 2016;98:91–8.PubMedCrossRef

Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al. Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob Res. 2007;9(9):947–54.PubMedCrossRef

Piper ME, Baker TB, Benowitz NL, Kobinsky KH, Jorenby DE. Dual users compared to smokers: demographics, dependence, and biomarkers. Nicotine Tob Res. 2019;21(9):1279–84.PubMedCrossRef

Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet. 2013;381(9861):133–41.PubMedPubMedCentralCrossRef

Pisinger C, Døssing M. A systematic review of health effects of electronic cigarettes. Prev Med. 2014;69:248–60.PubMedCrossRef

Polosa R, Morjaria JB, Caponnetto P, Caruso M, Campagna D, Amaradio MD, et al. Persisting long term benefits of smoking abstinence and reduction in asthmatic smokers who have switched to electronic cigarettes. Discov Med. 2016a;21(114):99–108.PubMed

Polosa R, Morjaria JB, Caponnetto P, Prosperini U, Russo C, Pennisi A, et al. Evidence for harm reduction in COPD smokers who switch to electronic cigarettes. Respir Res. 2016b;17(1):166.PubMedPubMedCentralCrossRef

Prestwich A, Moore S, Kotze A, Budworth L, Lawton R, Kellar I. How can smoking cessation be induced before surgery? A systematic review and meta-analysis of behavior change techniques and other intervention characteristics. Front Psychol. 2017;8:915.PubMedPubMedCentralCrossRef

Prochaska JO. Stages of change model for smoking prevention and cessation in schools: authors applied adult dose for smoking to adolescents when smoking behaviour is different in the two. BMJ. 2000;320(7232):447.PubMedPubMedCentralCrossRef

Prokopowicz A, Sobczak A, Szuła-Chraplewska M, Ochota P, Kośmider L. Exposure to cadmium and lead in cigarette smokers who switched to electronic cigarettes. Nicotine Tob Res. 2019;21(9):1198–205.PubMedCrossRef

Rahman MA, Edward K-L, Montgomery L, McEvedy S, Wilson A, Worrall-Carter L. Is there any gender difference for smoking persistence or relapse following diagnosis or hospitalization for coronary heart disease? Evidence from a systematic review and meta-analysis. Nicotine Tob Res. 2016;18(6):1399–407.PubMedCrossRef

Ramos M, Ripoll J, Estrades T, Socias I, Fe A, Duro R, et al. Effectiveness of intensive group and individual interventions for smoking cessation in primary health care settings: a randomized trial. BMC Public Health. 2010;10(1):1–6.CrossRef

Rasch A, Greiner W. Efficacy and cost-effectiveness of smoking cessation courses in the statutory health insurance: a review. Gesundheitswesen. 2009;71(11):732–8.PubMedCrossRef

Raupach T, Schäfer K, Konstantinides S, Andreas S. Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. Eur Heart J. 2006;27(4):386–92.PubMedCrossRef

Raupach T, Strobel L, Beard E, Krampe H, Anders S, West R. German medical students’ beliefs about the effectiveness of different methods of stopping smoking. Nicotine Tob Res. 2013;15(11):1892–901.PubMedCrossRef

Raupach T, Krampe H, Brown J. Does research into medical education on tobacco and alcohol get the respect it deserves. Addiction. 2014;109(2):173–4.PubMedCrossRef

Reda AA, Kotz D, Evers S, van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev. 2012;(6):Art. No.: CD004305. https://doi.org/10.1002/14651858.CD004305.pub4.

Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M, et al. Efficacy of the nicotine inhaler in smoking reduction: a double-blind, randomized trial. Nicotine Tob Res. 2006;8(4):555–64.PubMedCrossRef

Revenstorf D. Schaden durch Hypnose. Hypnose-ZHH. 2011;6(1):2.

Rice VH, Heath L, Livingstone-Banks J, Hartmann-Boyce J. Nursing interventions for smoking cessation. Cochrane Database Syst Rev. 2017;(12):Art. No.: CD001188. https://doi.org/10.1002/14651858.CD001188.pub5.

Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction. 2009;104(2):266–76.PubMedCrossRef

Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2012;(5):Art. No.: CD001837. https://doi.org/10.1002/14651858.CD001837.pub3.

Roberts E, Eden Evins A, McNeill A, Robson D. Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. Addiction. 2016;111(4):599–612.PubMedPubMedCentralCrossRef

Rohsenow DJ, Tidey JW, Miranda R Jr, McGeary JE, Swift RM, Hutchison KE, et al. Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers. Exp Clin Psychopharmacol. 2008;16(3):215–22.PubMedCrossRef

van Rossem C, Spigt M, Viechtbauer W, Lucas AE, van Schayck OC, Kotz D. Effectiveness of intensive practice nurse counselling versus brief general practitioner advice, both combined with varenicline, for smoking cessation: a randomized pragmatic trial in primary care. Addiction. 2017;112(12):2237–47.PubMedCrossRef

Rostron BL, Corey CG, Chang JT, van Bemmel DM, Miller ME, Chang CM. Associations of cigarettes smoked per day with biomarkers of exposure among US adult cigarette smokers in the Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013–2014). Cancer Epidemiol Prev Biomarkers. 2019;28(9):1443–53.CrossRef

Rubinstein ML, Benowitz NL, Auerback GM, Moscicki A-B. A randomized trial of nicotine nasal spray in adolescent smokers. Pediatrics. 2008;122(3):e595–600.PubMedCrossRef

Rüther T, Bobes J, De Hert M, Svensson T, Mann K, Batra A, et al. EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry. 2014;29(2):65–82.PubMedCrossRef

Saba M, Diep J, Saini B, Dhippayom T. Meta-analysis of the effectiveness of smoking cessation interventions in community pharmacy. J Clin Pharm Ther. 2014;39(3):240–7.PubMedCrossRef

Salize HJ, Merkel S, Reinhard I, Twardella D, Mann K, Brenner H. Cost-effective primary care–based strategies to improve smoking cessation: more value for money. Arch Intern Med. 2009;169(3):230–5.PubMedCrossRef

Sargent JD, Demidenko E, Malenka DJ, Li Z, Gohlke H, Hanewinkel R. Smoking restrictions and hospitalization for acute coronary events in Germany. Clin Res Cardiol. 2012;101(3):227–35.PubMedPubMedCentralCrossRef

Saules KK, Schuh LM, Arfken CL, Reed K, Kilbey MM, Schuster CR. Double-blind placebo-controlled trial of fluoxetine in smoking cessation treatment including nicotine patch and cognitive-behavioral group therapy. Am J Addict. 2004;13(5):438–46.PubMedCrossRef

Schaller K, Mons U. E-Zigaretten: gesundheitliche Bewertung und potenzieller Nutzen für Raucher. Pneumologie. 2018;72(06):458–72.PubMedCrossRef

Schepis TS, Rao U. Smoking cessation for adolescents: a review of pharmacological and psychosocial treatments. Curr Drug Abuse Rev. 2008;1(2):142–54.PubMedPubMedCentralCrossRef

Schleicher HE, Harris KJ, Campbell DG, Harrar SW. Mood management intervention for college smokers with elevated depressive symptoms: a pilot study. J Am Coll Heal. 2012;60(1):37–45.CrossRef

Schmelzle J, Rosser WW, Birtwhistle R. Update on pharmacologic and nonpharmacologic therapies for smoking cessation. Can Fam Physician. 2008;54(7):994–9.PubMedPubMedCentral

Schofield I. Supporting older people to quit smoking. Nurs Older People. 2006;18(6):29–34.PubMedCrossRef

Schofield I, Kerr S, Tolson D. An exploration of the smoking-related health beliefs of older people with chronic obstructive pulmonary disease. J Clin Nurs. 2007;16(9):1726–35.PubMedCrossRef

Scott-Sheldon LA, Lantini RC, Jennings EG, Thind H, Rosen RK, Salmoirago-Blotcher E, et al. Text messaging-based interventions for smoking cessation: a systematic review and meta-analysis. JMIR mHealth uHealth. 2016;4(2):e49.PubMedPubMedCentralCrossRef

Secades-Villa R, González-Roz A, García-Pérez Á, Becoña E. Psychological, pharmacological, and combined smoking cessation interventions for smokers with current depression: a systematic review and meta-analysis. PLoS One. 2017;12(12):e0188849.PubMedPubMedCentralCrossRef

Shahab L, Goniewicz ML, Blount BC, Brown J, McNeill A, Alwis KU, et al. Nicotine, carcinogen, and toxin exposure in long-term e-cigarette and nicotine replacement therapy users: a cross-sectional study. Ann Intern Med. 2017;166(6):390–400.PubMedPubMedCentralCrossRef

Shields PG, Berman M, Brasky TM, Freudenheim JL, Mathe E, McElroy JP, et al. A review of pulmonary toxicity of electronic cigarettes in the context of smoking: a focus on inflammation. Cancer Epidemiol Prev Biomarkers. 2017;26(8):1175–91.CrossRef

Simonavicius E, McNeill A, Shahab L, Brose LS. Heat-not-burn tobacco products: a systematic literature review. Tob Control. 2019;28(5):582–94.PubMedCrossRef

Sliwińska-Mossoń M, Zieleń I, Milnerowicz H. New trends in the treatment of nicotine addiction. Acta Pol Pharm. 2014;71(4):525–30.PubMed

Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–73.PubMedCrossRef

Smith PH, Bessette AJ, Weinberger AH, Sheffer CE, McKee SA. Sex/gender differences in smoking cessation: a review. Prev Med. 2016;92:135–40.PubMedPubMedCentralCrossRef

Smith PH, Weinberger AH, Zhang J, Emme E, Mazure CM, McKee SA. Sex differences in smoking cessation pharmacotherapy comparative efficacy: a network meta-analysis. Nicotine Tob Res. 2017;19(3):273–81.PubMed

Smith SS, Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, et al. Targeting smokers at increased risk for relapse: treating women and those with a history of depression. Nicotine Tob Res. 2003;5(1):99–109.PubMedCrossRef

Soneji S, Barrington-Trimis JL, Wills TA, Leventhal AM, Unger JB, Gibson LA, et al. Association between initial use of e-cigarettes and subsequent cigarette smoking among adolescents and young adults: a systematic review and meta-analysis. JAMA Pediatr. 2017;171(8):788–97.PubMedPubMedCentralCrossRef

Sood A, Ebbert JO, Sood R, Stevens SR. Complementary treatments for tobacco cessation: a survey. Nicotine Tob Res. 2006;8(6):767–71.PubMedCrossRef

Sood A, Ebbert J, Prasad K. J Altern Complement Med: a randomized clinical trial of St. John’s wort for smoking cessation. Altern Med Rev. 2010a;15(4):376–7.

Sood A, Ebbert JO, Wyatt KD, Croghan IT, Schroeder DR, Sood R, et al. Gabapentin for smoking cessation. Nicotine Tob Res. 2010b;12(3):300–4.PubMedPubMedCentralCrossRef

de Souza ICW, de Barros VV, Gomide HP, Miranda TCM, de Paula MV, Kozasa EH, et al. Mindfulness-based interventions for the treatment of smoking: a systematic literature review. J Altern Complement Med. 2015;21(3):129–40.PubMedCrossRef

Spring B, Doran N, Pagoto S, McChargue D, Cook JW, Bailey K, et al. Fluoxetine, smoking, and history of major depression: a randomized controlled trial. J Consult Clin Psychol. 2007;75(1):85.PubMedCrossRef

Stanton A, Grimshaw G. Tobacco cessation interventions for young people. Cochrane Database Syst Rev. 2013;(8):Art. No.: CD003289. https://doi.org/10.1002/14651858.CD003289.pub5.

Stapleton J, West R, Hajek P, Wheeler J, Vangeli E, Abdi Z, et al. Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction. 2013;108(12):2193–201.PubMedPubMedCentralCrossRef

Stead LF, Lancaster T. Nicobrevin for smoking cessation. Cochrane Database Syst Rev. 2006;(2):Art. No.: CD005990. https://doi.org/10.1002/14651858.CD005990.

Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012;11:Art. No.: CD000146. https://doi.org/10.1002/14651858.CD000146.pub4.CrossRef

Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013;(5):Art. No.: CD000165. https://doi.org/10.1002/14651858.CD000165.pub4.

Stead LF, Koilpillai P, Lancaster T. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2015;(10):Art. No.: CD009670. https://doi.org/10.1002/14651858.CD009670.pub3.

Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016;(3):Art. No.: CD008286. https://doi.org/10.1002/14651858.CD008286.pub3.

Stead LF, Carroll AJ, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2017;(3):Art. No.: CD001007. https://doi.org/10.1002/14651858.CD001007.pub3.

Stephens WE. Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke. Tob Control. 2018;27(1):10–7.CrossRef

Suissa K, Larivière J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes. 2017;10(1).

Sussman S, Sun P, Dent CW. A meta-analysis of teen cigarette smoking cessation. Health Psychol. 2006;25(5):549.PubMedCrossRef

Szatkowski L, McNeill A. The delivery of smoking cessation interventions to primary care patients with mental health problems. Addiction. 2013;108(8):1487–94.PubMedCrossRef

Tahiri M, Mottillo S, Joseph L, Pilote L, Eisenberg MJ. Alternative smoking cessation aids: a meta-analysis of randomized controlled trials. Am J Med. 2012;125(6):576–84.PubMedCrossRef

Tait RJ, Hulse GK, Waterreus A, Flicker L, Lautenschlager NT, Jamrozik K, et al. Two-year outcomes from a cessation of smoking intervention in older adults. J Smok Cessat. 2008;3(2):101.CrossRef

Tanner NT, Kanodra NM, Gebregziabher M, Payne E, Halbert CH, Warren GW, et al. The association between smoking abstinence and mortality in the national lung screening trial. Am J Respir Crit Care Med. 2016;193(5):534–41.PubMedCrossRef

Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011;139(3):591–9.PubMedCrossRef

Taylor GMJ, Dalili MN, Semwal M, Civljak M, Sheikh A, Car J. Internet-based interventions for smoking cessation. Cochrane Database Syst Rev. 2017;(9):Art. No.: CD007078. https://doi.org/10.1002/14651858.CD007078.pub5.

Taylor DH Jr, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health. 2002;92(6):990–6.PubMedPubMedCentralCrossRef

The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) (Eds.). Guidelines on the management of valvular heart disease (version 2012). European Heart Journal 2012;(33):2451–2496. https://doi.org/10.1093/eurheartj/ehs109.

Thomas D, Abramson MJ, Bonevski B, George J. System change interventions for smoking cessation. Cochrane Database Syst Rev. 2017;(2):Art. No.: CD010742. https://doi.org/10.1002/14651858.CD010742.pub2.

Thomsen T, Villebro N, Møller AM. Interventions for preoperative smoking cessation. Cochrane Database Syst Rev. 2014;(3):Art. No.: CD002294. https://doi.org/10.1002/14651858.CD002294.pub4.

Thorsteinsson HS, Gillin JC, Patten CA, Golshan S, Sutton LD, Drummond S, et al. The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. Neuropsychopharmacology. 2001;24(4):350–8.PubMedCrossRef

Thurgood SL, McNeill A, Clark-Carter D, Brose LS. A systematic review of smoking cessation interventions for adults in substance abuse treatment or recovery. Nicotine Tob Res. 2016;18(5):993–1001.PubMedCrossRef

Tønnesen P, Mikkelsen K, Bremann L. Smoking cessation with smokeless tobacco and group therapy: an open, randomized, controlled trial. Nicotine Tob Res. 2008;10(8):1365–72.PubMedCrossRef

Torchalla I, Okoli CT, Bottorff JL, Qu A, Poole N, Greaves L. Smoking cessation programs targeted to women: a systematic review. Women Health. 2012;52(1):32–54.PubMedCrossRef

Trtchounian A, Williams M, Talbot P. Conventional and electronic cigarettes (e-cigarettes) have different smoking characteristics. Nicotine Tob Res. 2010;12(9):905–12.PubMedCrossRef

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, et al. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016;11(5):613–38.PubMedCrossRef

Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;(2):Art. No.: CD007253. https://doi.org/10.1002/14651858.CD007253.pub3.

Turner E, Jones M, Vaz LR, Coleman T. Systematic review and meta-analysis to assess the safety of bupropion and varenicline in pregnancy. Nicotine Tob Res. 2019;21(8):1001–10.PubMedCrossRef

Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption. Tob Control. 2006;15(6):472–80.PubMedPubMedCentralCrossRef

U.S. Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the surgeon general. Rockville: U.S. Department of Health and Human Services;2014a.

Veldheer S, Yingst J, Midya V, Hummer B, Lester C, Krebs N, et al. Pulmonary and other health effects of electronic cigarette use among adult smokers participating in a randomized controlled smoking reduction trial. Addict Behav. 2019;91:95–101.PubMedCrossRef

Vickers KS, Patten CA, Lewis BA, Clark MM, Ussher M, Ebbert JO, et al. Feasibility of an exercise counseling intervention for depressed women smokers. Nicotine Tob Res. 2009;11(8):985–95.PubMedPubMedCentralCrossRef

Vineis P, Kogevinas M, Simonato L, Brennan P, Boffetta P. Levelling-off of the risk of lung and bladder cancer in heavy smokers: an analysis based on multicentric case-control studies and a metabolic interpretation. Mutat Res. 2000;463(1):103–10.PubMed

Vogeler T, McClain C, Evoy KE. Combination bupropion SR and varenicline for smoking cessation: a systematic review. Am J Drug Alcohol Abuse. 2016;42(2):129–39.PubMedCrossRef

Vogelmeier C, Buhl R, Burghuber O, Criée C-P, Ewig S, Godnic-Cvar J, et al. Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie. 2018;72(04):253–308.PubMedCrossRef

Wagena EJ, de Vos A, Horwith G, van Schayck CP. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob Res. 2008;10(1):213–8.PubMedCrossRef

Walker N, Parag V, Verbiest M, Laking G, Laugesen M, Bullen C. Nicotine patches used in combination with e-cigarettes (with and without nicotine) for smoking cessation: a pragmatic, randomised trial. Lancet Respir Med. 2020;8(1):54–64.PubMedCrossRef

Walsh Z, Epstein A, Munisamy G, King A. The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. J Addict Dis. 2008;27(1):65–72.PubMedCrossRef

Wang J-H, van Haselen R, Wang M, Yang G-L, Zhang Z, Friedrich ME, et al. Acupuncture for smoking cessation: a systematic review and meta-analysis of 24 randomized controlled trials. Tob Induc Dis. 2019;17:48.PubMedPubMedCentralCrossRef

Wang J-W, Cao S-S, Hu R-Y. Smoking by family members and friends and electronic-cigarette use in adolescence: a systematic review and meta-analysis. Tob Induc Dis. 2018;16:05.PubMedPubMedCentralCrossRef

Wasem J, Jung M, May U, Ochotta T, Hessel F, Wegner C, et al. Nutzen und Kosteneffektivität der Nikotinersatztherapie zur Raucherentwöhnung-eine entscheidungsanalytische Modellierung der direkten medizinischen Kosten. Gesundheitsökonomie Qualitätsmanagement. 2008;13(02):99–108.CrossRef

van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenet Genomics. 2003;13(3):169–72.CrossRef

Weinberger AH, Reutenauer EL, Jatlow PI, O’Malley SS, Potenza MN, George TP. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend. 2010;107(2–3):188–95.PubMedCrossRef

Weinberger AH, Smith PH, Kaufman M, McKee SA. Consideration of sex in clinical trials of transdermal nicotine patch: a systematic review. Exp Clin Psychopharmacol. 2014;22(5):373–83.PubMedPubMedCentralCrossRef

Westerdahl E, Engman KO, Arne M, Larsson M. Spirometry to increase smoking cessation rate: A systematic review. Tob Induc Dis. 2019;17.

White AR, Rampes H, Liu JP, Stead LF, Campbell J. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev. 2011;(1):Art. No.: CD000009. https://doi.org/10.1002/14651858.CD000009.pub3.

Whitson HE, Heflin MT, Burchett BM. Patterns and predictors of smoking cessation in an elderly cohort. J Am Geriatr Soc. 2006;54(3):466–71.PubMedCrossRef

Whittaker R, McRobbie H, Bullen C, Rodgers A, Gu Y. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev. 2016;(4):Art. No.: CD006611. https://doi.org/10.1002/14651858.CD006611.pub4.

Whyte S, Penny C, Phelan M, Hippisley-Cox J, Majeed A. Quality of diabetes care in patients with schizophrenia and bipolar disorder: cross-sectional study. Diabet Med. 2007;24(12):1442–8.PubMedCrossRef

Wiggers LC, Smets EM, Oort FJ, Peters RJ, Storm-Versloot MN, Vermeulen H, et al. The effect of a minimal intervention strategy in addition to nicotine replacement therapy to support smoking cessation in cardiovascular outpatients: a randomized clinical trial. Eur J Cardiovasc Prev Rehabil. 2006;13(6):931–7.PubMedCrossRef

Williams M, Talbot P. Variability among electronic cigarettes in the pressure drop, airflow rate, and aerosol production. Nicotine Tob Res. 2011;13(12):1276–83.PubMedCrossRef

Wilson SM, Newins AR, Medenblik AM, Kimbrel NA, Dedert EA, Hicks TA, et al. Contingency management versus psychotherapy for prenatal smoking cessation: a meta-analysis of randomized controlled trials. Womens Health Issues. 2018;28(6):514–23.PubMedPubMedCentralCrossRef

Windle SB, Filion KB, Mancini JG, Adye-White L, Joseph L, Gore GC, et al. Combination therapies for smoking cessation: a hierarchical Bayesian meta-analysis. Am J Prev Med. 2016;51(6):1060–71.PubMedCrossRef

World Health Organization. WHO report on the global tobacco epidemic 2019: Offer help to quit tobacco use. 2019.

Wu L, Sun S, He Y, Zeng J. Effect of smoking reduction therapy on smoking cessation for smokers without an intention to quit: an updated systematic review and meta-analysis of randomized controlled. Int J Environ Res Public Health. 2015;12(9):10235–53.PubMedPubMedCentralCrossRef

Wu Q, Gilbody S, Peckham E, Brabyn S, Parrott S. Varenicline for smoking cessation and reduction in people with severe mental illnesses: systematic review and meta-analysis. Addiction. 2016;111(9):1554–67.PubMedCrossRef

Wu T-P, Chen F-P, Liu J-Y, Lin M-H, Hwang S-J. A randomized controlled clinical trial of auricular acupuncture in smoking cessation. J Chin Med Assoc. 2007;70(8):331–8.PubMedCrossRef

Wynd CA. Guided health imagery for smoking cessation and long-term abstinence. J Nurs Scholarsh. 2005;37(3):245–50.PubMedCrossRef

Yoong SL, Stockings E, Chai LK, Tzelepis F, Wiggers J, Oldmeadow C, et al. Prevalence of electronic nicotine delivery systems (ENDS) use among youth globally: a systematic review and meta-analysis of country level data. Aust N Z J Public Health. 2018;42(3):303–8.PubMedCrossRef

Young CL, Trapani K, Dawson S, O’Neil A, Kay-Lambkin F, Berk M, et al. Efficacy of online lifestyle interventions targeting lifestyle behaviour change in depressed populations: a systematic review. Austr N Z J Psychiatry. 2018;52(9):834–46.CrossRef

Zbikowski SM, Magnusson B, Pockey JR, Tindle HA, Weaver KE. A review of smoking cessation interventions for smokers aged 50 and older. Maturitas. 2012;71(2):131–41.PubMedCrossRef

Zeng L, Yu X, Yu T, Xiao J, Huang Y. Interventions for smoking cessation in people diagnosed with lung cancer. Cochrane Database Syst Rev. 2019;(6):Art. No.: CD011751. https://doi.org/10.1002/14651858.CD011751.pub3.

Zernig G, Wallner R, Grohs U, Kriechbaum N, Kemmler G, Saria A. A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. Addiction. 2008;103(12):2024–31.PubMedCrossRef

Zhang JJ, Fong KN, Rg O, Siu AM, Kranz GS. Effects of repetitive transcranial magnetic stimulation (rTMS) on craving and substance consumption in patients with substance dependence: a systematic review and meta-analysis. Addiction. 2019;114(12):2137–49.PubMedCrossRef

Titel: Behandlung von schädlichem und abhängigem Tabakkonsum
verfasst von: Stefan Andreas
Anil Batra
Dörthe Brüggmann
Dieter Geyer
Helmut Gohlke
Thomas Hering
Andreas Jähne
Julia Jückstock
Marianne Klein
Daniel Kotz
Christoph Kröger
Timo Krüger
Michael Kölch
Evelyn Lesta
Johannes Lindenmeyer
Peter Lindinger
Ute Mons
Stephan Mühlig
Tim Neumann
Kay Uwe Petersen
Thomas Polak
Ulrich W. Preuss
Martina Pötschke-Langer
Christa Rustler
Tobias Rüther
Sophie Luise Schiller
Christiane Schwarz
Cornelie Schweizer
Rainer Thomasius
Sabina Ulbricht
Clemens Veltrup
Verlag: Springer Berlin Heidelberg
Buch: S3-Leitlinie Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung
Print ISBN: 978-3-662-63678-7

Electronic ISBN: 978-3-662-63679-4

Copyright-Jahr: 2022
DOI: https://doi.org/10.1007/978-3-662-63679-4_4

Passend zum Thema

COPD und nicht-invasive Behandlungsmethoden

Content Hub

Nicht-medikamentöse Behandlungsmethoden wie die nicht-invasive Beatmung (NIV) können die Leistungsfähigkeit und Lebensqualität von COPD-Patienten erheblich verbessern und das Sterberisiko senken. Die NIV-Therapie zur Behandlung von fortgeschrittener COPD hat Eingang in die neuen S2k-Leitlinien zur COPD-Therapie gefunden.

Geringere Therapieabbruchquoten durch digitale Therapiebegleitung

Ärzte profitieren von digitaler Therapiebegleitung ihrer NIV-Patienten durch einen verlässlichen Partner, weil diese sich besser versorgt fühlen und die Therapie weniger häufig abbrechen. Das entlastet das Gesundheitssystem und schwer Erkrankte gewinnen Lebensqualität.

Auch für ältere Patienten empfiehlt sich nicht-invasive Langzeitbeatmung

Nicht-invasive Beatmung ist für Menschen mit chronisch hyperkapnisch respiratorischer Insuffizienz eine bewährte Therapie. Eine Schweizer Studie untersuchte die Auswirkungen der Beatmung auf über 75-Jährige und belegt nun deren Wirksamkeit.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

4. Behandlung von schädlichem und abhängigem Tabakkonsum

Zusammenfassung

Passend zum Thema

COPD und nicht-invasive Behandlungsmethoden

Geringere Therapieabbruchquoten durch digitale Therapiebegleitung

Auch für ältere Patienten empfiehlt sich nicht-invasive Langzeitbeatmung

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Passend zum Thema

COPD und nicht-invasive Behandlungsmethoden

Geringere Therapieabbruchquoten durch digitale Therapiebegleitung

Auch für ältere Patienten empfiehlt sich nicht-invasive Langzeitbeatmung